Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis | BMJ Neurology Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Topic collection

Archive

For authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis - July 01, 2021

XML

Short report

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

	Abstract	Full	Pdf
May 2021	109	110	49
Jun 2021	226	226	75
Jul 2021	136	136	44
Aug 2021	155	156	35
Sep 2021	193	193	52
Oct 2021	127	130	44
Nov 2021	128	128	27
Dec 2021	117	117	9
Jan 2022	121	122	23
Feb 2022	93	96	13
Mar 2022	93	99	17
Apr 2022	90	91	9
May 2022	111	113	17
Jun 2022	59	59	10
Jul 2022	72	73	8
Aug 2022	71	71	47
Sep 2022	53	53	15
Oct 2022	78	80	11
Nov 2022	38	38	7
Dec 2022	31	31	5
Jan 2023	25	27	10
Feb 2023	54	56	10
Mar 2023	96	107	22
Apr 2023	33	33	13
May 2023	39	40	15
Jun 2023	33	35	12
Jul 2023	22	23	7
Aug 2023	46	48	10
Sep 2023	30	33	11
Oct 2023	32	32	13
Nov 2023	37	39	9
Dec 2023	48	48	10
Jan 2024	36	36	22
Feb 2024	28	28	15
Mar 2024	25	25	76
Total	2685	2732	772